Inflammation, infection, and coronary heart disease

European Heart Journal

Volumn 23, Issue 5, 2002, Pages 343-344

  Wilhelmsen, L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY;

ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CORONARY RISK; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ANIMALS; CORONARY DISEASE; HUMANS; INFECTION; INFLAMMATION;

EID: 0036522281     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2956     Document Type: Editorial

References (16)

1. Danesh J, Whincup P, Lewington S et al. Chlamydia pneumoniae IgA titres and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2002; 23: 371-5, doi: 10.1053/euhj.2001.2801
2. Wilhelmsen L. Coronary heart disease: Epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242-9.
3. Böttiger LE, Carlson LA. Risk factors for ischaemic vascular death for men in the Stockholm prospective study. Atherosclerosis 1980; 36: 389-408.
4. Shah PK. Plaque disruption and thrombosis. Potential role of inflammation and infection. Cardiol Rev 2000; 8: 31-9.
5. Jahn J, Dalhoff K, Katus HA. Coronary artery disease: An inflammatory or infectious process. Basic Res Cardiol 2000; 95 (Suppl 1): 59-64.
6. Becker AE, de Boer OJ, van der Wall AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med 2001; 52: 289-97.
7. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
8. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 503-5.
9. Lee RT, Schoen RT, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996; 16: 1070-3.
10. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 8618: 983-6.
11. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-6.
12. Mass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomen in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32.
13. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with Chlamydia pneumniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
14. Moazed TC, Kuo C, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumomiae via macrophages in the mouse. J Infect Dis 1997; 177: 1322-5.
15. Kothe H, Dalhoff K, Rupp J et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760-3.
16. Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-8.